Clinical trials · Rhode Island
Alzheimer’s disease clinical trials in Rhode Island
We’re tracking 13 recruiting alzheimer’s disease studies with a site in Rhode Island — including Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Rhode Island
- NCT07167966Enrolling by invitationPhase 2
Alzheimer's tau vaccine study (AADvac1)
This trial tests a vaccine that targets tau tangles in the brain, which are linked to Alzheimer's. It is part of a larger platform study that combines different experimental treatments.
Providence, Rhode IslandAges 50–80 - NCT06957418RecruitingPhase 2
Alzheimer's tau drug study for early stage patients
This trial tests a treatment targeting tau protein buildup in the brain for people with early Alzheimer's. You may join if you have memory or thinking changes but are still living independently, and brain scans show both amyloid and tau clumps.
Providence, Rhode IslandAges 50–80 - NCT06416072Enrolling by invitation
Blood marker study for people not eligible for Alzheimer's prevention trials
This study looks at blood markers in people who were part of an early Alzheimer's prevention study but did not qualify for it because their amyloid levels were too low. It aims to understand brain changes and possibly find ways to detect Alzheimer's even earlier.
Providence, Rhode IslandAges 55–80 - NCT06647498RecruitingPhase 2/Phase 3
Study of a treatment for early-onset Alzheimer's caused by a gene change
This study tests a potential disease-modifying treatment for people who have a specific gene mutation that causes early-onset Alzheimer's disease. The goal is to see if the treatment can delay or prevent symptoms.
Providence, Rhode IslandAges 18 years+ - NCT05552157RecruitingPhase 2/Phase 3
Study of treatments for early onset Alzheimer's caused by genetic mutations
This trial tests potential treatments for people who are at risk for or have early onset Alzheimer's disease due to a specific genetic mutation. It aims to find treatments that could slow or prevent symptoms.
Providence, Rhode IslandAges 18 years+ - NCT07177352RecruitingPhase 3
Screening for Roche Alzheimer's studies
This is a screening study to find people who might be eligible for other Alzheimer's drug studies run by the same company. It helps match you to a treatment trial if you qualify.
Providence, Rhode IslandAges 50–90 - NCT06976216RecruitingPhase 3
Study of KarXT plus KarX-EC for Alzheimer's cognitive symptoms
This trial tests a new combination treatment (KarXT plus KarX-EC) to see if it can help with thinking and memory problems caused by Alzheimer's disease. It is for people with mild to moderate Alzheimer's who have a caregiver available.
East Providence, Rhode IslandAges 60–85 - NCT06584357Recruiting
Digital and blood markers linked to brain scans in older adults
This study is looking for older adults (60–90) who are either cognitively normal, have mild cognitive impairment (MCI), or have mild-to-moderate Alzheimer's dementia. It aims to see how digital tests and blood-based markers relate to brain scans (amyloid and tau PET). You will need a study partner, undergo MRI and PET scans, and give blood samples.
East Providence, Rhode IslandAges 60–90 - NCT05457998Enrolling by invitation
Study of Alzheimer’s brain markers using memory testing
This trial looks for signs of Alzheimer’s disease in the brain by using memory and thinking tests, and related study procedures. It may help researchers find better ways to identify Alzheimer’s-related changes earlier.
Providence, Rhode IslandAges 50–80 - NCT06585787RecruitingPhase 3
Testing KarXT for psychosis in Alzheimer’s disease
This study tests an investigational medication (KarXT) for treating psychosis—hallucinations or delusions—in people with Alzheimer’s disease. It aims to see if the drug can reduce these symptoms safely and effectively.
Providence, Rhode IslandAges 55–90 - NCT05617014Enrolling by invitation
ADNI4 study for early Alzheimer’s with brain imaging tests
This study enrolls people with no memory impairment, mild memory problems, or mild Alzheimer’s dementia to test how brain scans and cognitive tests relate to Alzheimer’s disease. It may help by contributing to better early diagnosis and by letting you see whether you fit into the study’s imaging and blood-test pathway.
Providence, Rhode IslandAges 55–90 - NCT05980949RecruitingPhase 3
Long-term safety study of KarXT for Alzheimer's psychosis
This trial tests the long-term safety of an investigational drug called KarXT for people with psychosis caused by Alzheimer's disease. It is for those who have already completed a previous KarXT study and want to continue treatment.
Providence, Rhode IslandAges 55–90 - NCT00869817Recruiting
Study for adults at risk of inherited Alzheimer’s
This study follows people who are at risk for a specific inherited form of Alzheimer’s disease (because a parent has it). It helps researchers learn how the disease starts and changes over time, especially in people who still feel cognitively normal.
Providence, Rhode IslandAges 18 years+
Alzheimer’s disease trials by city in Rhode Island
Where these studies are running in Rhode Island
Institutions with a site for the recruiting alzheimer’s disease studies listed above.
- Butler Hospital · 4 studies
- Butler Hospital Memory and Aging Program · 4 studies
- Alzheimer's Disease and Memory Disorders Center at Rhode Island Hospital
- Butler Hospital, Memory and Aging Program
- K2 Medical Research
- Local Institution - 1218
- Rhode Island Hospital
- Rhode Island Mood & Memory Research Institute
What taking part in a alzheimer’s disease study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Alzheimer’s disease trials in other states
Common questions
- Are there alzheimer’s disease clinical trials in Rhode Island?
- Yes. We're currently tracking 13 recruiting alzheimer’s disease studies with a site in Rhode Island, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a alzheimer’s disease study in Rhode Island?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Rhode Island to take part?
- Not necessarily. These studies have a site in Rhode Island, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a alzheimer’s disease trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New alzheimer’s disease studies open in Rhode Island regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.